NASDAQ$NRC
NRC Health · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced results for the third quarter 2023.
NRC Health's third quarter 2023 saw increased new sales compared to the third quarter of 2022, driven by growth in the Human Understanding Program, which was adopted by 91 healthcare organizations. The company is focused on controlling costs and has achieved sequential quarterly operating margin improvement. NRC remains well-positioned to execute capital allocation alternatives, including innovation, growth investments, shareholder dividends, and share repurchases.
- New sales increased compared to Q3 2022, driven by the Human Understanding Program.
- 91 healthcare organizations adopted the Human Understanding Program as of September 30, 2023.
- Sequential quarterly operating margin improvement was realized in the last two quarters.
- NRC remains well-positioned to execute capital allocation alternatives.
Headline financials
Revenue & EPS history
NRC · Revenue · Quarterly
$37.9M
Forward guidance
NRC Health is focused on controlling costs in an inflationary environment and returning to historical operating margins. The company is well-positioned to execute capital allocation alternatives, including funding innovation and growth investments, shareholder dividends and share repurchases.
Tailwinds
- Focus on controlling costs in an inflationary environment.
- Sequential quarterly operating margin improvement in the last two quarters.
- Emphasis on returning to historical operating margins.
- Well-positioned to execute the entire range of capital allocation alternatives.
- Funding innovation and growth investments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.3%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+16.1%
Q3 2025
Best reaction
-19.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +7.9% | +16.0% | |
| Q4 2025 | -19.9% | -27.2% | -35.9% | |
| Q3 2025 | +16.1% | +17.0% | +51.2% | |
| Q2 2025 | +2.1% | +4.8% | +6.7% | |
| Q1 2025 | +7.0% | +7.6% | +20.2% | |
| Q4 2024 | -11.9% | -11.0% | -22.6% | |
| Q3 2024 | +2.6% | -2.1% | +4.5% | |
| Q2 2024 | -11.7% | -9.3% | -7.2% | |
| Q1 2024 | -15.3% | -11.6% | -23.7% | |
| Q4 2023 | +2.2% | +0.6% | +1.7% | |
| Q3 2023 | -1.9% | -0.3% | -1.1% | |
| Q2 2023 | +2.2% | -0.4% | -2.6% | |
| Q1 2023 | -8.3% | -5.2% | -1.2% | |
| Q4 2022 | +4.8% | +5.3% | -1.8% | |
| Q3 2022 | -13.5% | -8.3% | -3.5% | |
| Q2 2022 | -4.1% | -7.4% | -12.8% | |
| Q1 2022 | -5.3% | -3.6% | +5.0% | |
| Q4 2021 | -1.5% | -4.5% | -4.7% | |
| Q3 2021 | +6.7% | +6.7% | -8.1% | |
| Q2 2021 | -0.8% | -0.2% | +1.6% | |
| Q1 2021 | -10.2% | -5.1% | -7.0% | |
| Q4 2020 | -0.7% | -3.9% | +0.3% | |
| Q3 2020 | +1.8% | -0.1% | -7.8% | |
| Q2 2020 | -4.1% | -1.0% | -3.0% | |
| Q1 2020 | +4.6% | +10.3% | +12.7% | |
| Q4 2019 | +0.3% | +1.8% | -36.0% | |
| Q3 2019 | -0.4% | +0.2% | +7.5% | |
| Q2 2019 | +3.0% | +2.6% | +1.0% | |
| Q1 2019 | +7.1% | +13.1% | +26.5% | |
| Q4 2018 | +0.6% | +2.7% | +0.2% | |
| Q3 2018 | +3.5% | +2.4% | +4.8% | |
| Q2 2018 | -0.3% | -0.3% | +2.4% | |
| Q1 2018 | +7.3% | +5.5% | +5.4% | |
| Q4 2017 | -7.4% | -7.9% | -9.7% | |
| Q3 2017 | -10.1% | -11.5% | -7.7% | |
| Q2 2017 | +0.9% | +1.7% | +9.9% | |
| Q1 2017 | +0.8% | -3.4% | -3.0% | |
| Q4 2016 | -3.0% | -4.9% | +0.5% | |
| Q3 2016 | -4.6% | -1.0% | +5.2% | |
| Q2 2016 | +0.3% | +2.3% | +2.2% | |
| Q1 2016 | +2.0% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | +3.8% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q4 2013 | +5.1% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | -1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro